Deutsch English Français

Contact

EP2729168

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2729168

EP2729168 - SELF-REPLICATING RNA PRIME - PROTEIN BOOST VACCINES [Right-click to bookmark this link]
Former [2014/20]	IMMUNOGENIC COMPOSITIONS AND USES THEREOF
	[2014/24]
Status	The application has been withdrawn Status updated on 30.11.2018 Database last updated on 27.07.2024
Former	Examination is in progress Status updated on 17.03.2017
Most recent event Tooltip	30.11.2018	New entry: Date of cancellation oral proceedings
	30.11.2018	Change - divisional application(s)	published on 02.01.2019 [2019/01]
	30.11.2018	Withdrawal of application	published on 02.01.2019 [2019/01]
	30.11.2018	Change - applicant	published on 02.01.2019 [2019/01]
Applicant(s)	For all designated states GlaxoSmithKline Biologicals SA Rue de l'Institut 89 1330 Rixensart / BE
	[2019/01]
Former [2014/20]	For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH
Inventor(s)	01 / GEALL, Andrew Novartis Vaccines and Diagnostics Inc. IP Services M/S X-100B 4560 Horton Street Emeryville, CA 94608-2916 / US
	02 / BARNETT, Susan c/o Novartis Vaccines and Diagnostics Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	03 / OTTEN, Gillis c/o Novartis Vaccines and Diagnostics Inc. P.O. Box 8097 Emeryville, CA 94662-8097 / US
	[2014/20]
Representative(s)	Courgeon, Antoine, et al GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2014/20]	Courgeon, Antoine, et al Novartis Vaccines and Diagnostics S.r.l. Intellectual Property Via Fiorentina, 1 53100 Siena / IT
Application number, filing date	12735421.5	06.07.2012
	WO2012US45854
Priority number, date	US201161505105P	06.07.2011 Original published format: US 201161505105 P
	[2014/20]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2013006842
	Date:	10.01.2013
	Language:	EN
	[2013/02]
	Type:	A2 Application without search report
	No.:	EP2729168
	Date:	14.05.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 10.01.2013 takes the place of the publication of the European patent application.
	[2014/20]
Search report(s)	International search report - published on:	EP	19.06.2014
	(Supplementary) European search report - dispatched on:	EP	16.03.2017
Classification	IPC:	A61K39/12, A61K39/295, A61P31/00, A61P11/00	[2014/20]
	CPC:	A61K39/155 (EP,US); A61K39/12 (EP,US); A61K39/245 (EP,US); A61P31/14 (EP,US); A61P31/20 (EP,US); A61K2039/53 (EP,US); (+) A61K2039/545 (EP,US); A61K2039/55505 (EP,US); A61K2039/55555 (EP,US); A61K2039/55566 (EP,US); A61K2039/55588 (EP,US); C12N2710/16134 (EP,US); C12N2760/18534 (EP,US); C12N2770/36143 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/20]
Title	German:	IMMUNOGENE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNGEN	[2014/20]
	English:	SELF-REPLICATING RNA PRIME - PROTEIN BOOST VACCINES	[2014/24]
	French:	COMPOSITIONS IMMUNOGÈNES ET LEURS UTILISATIONS	[2014/20]
	Former [2014/20]	IMMUNOGENIC COMPOSITIONS AND USES THEREOF
Entry into regional phase	06.02.2014	National basic fee paid
Examination procedure	04.02.2014	Amendment by applicant (claims and/or description)
	19.12.2014	Examination requested [2015/05]
	16.03.2017	Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M06) [2017/16]
	16.03.2017	Despatch of a communication from the examining division (Time limit: M06)
	26.09.2017	Reply to a communication from the examining division
	29.11.2018	Application withdrawn by applicant [2019/01]
	29.11.2018	Cancellation of oral proceeding that was planned for 30.11.2018
	30.11.2018	Date of oral proceedings (cancelled)
Divisional application(s)	EP18209088.6 / EP3508219
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 16.03.2017
Fees paid	Renewal fee
	14.07.2014	Renewal fee patent year 03
	10.07.2015	Renewal fee patent year 04
	11.07.2016	Renewal fee patent year 05
	10.07.2017	Renewal fee patent year 06
	10.07.2018	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XI]WO2005007689 (ALPHAVAX INC [US], et al) [X] 1-4,8-10,13,17-23,42-45,49,50,53,57-59,61 * page 21, paragraph 1 * * claims 19, 22, 23 * [I] 1-61;
		[YD]WO2011005799 (NOVARTIS AG [CH], et al) [YD] 1-61 * example 9 *;
		[A]WO2009042794 (UNIV VANDERBILT [US], et al) [A] 1-61 * abstract *;
		[AP]WO2012030901 (NOVARTIS AG [CH], et al) [AP] 1-61 * abstract *;
		[Y] - RONG XU ET AL, "Characterization of immune Responses Elicited in Macaques Immunized Sequentially with Chimeric VEE/SIN Alphavirus Replicon Particles Expressing SIVGag and/or HIVEnv and with Recombinant HIVgp140Env Protein", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, (20061001), vol. 22, no. 10, doi:10.1089/AID.2006.22.1022, ISSN 0889-2229, pages 1022 - 1030, XP002476924 [Y] 1-61 * the whole document * DOI: http://dx.doi.org/10.1089/aid.2006.22.1022
		[Y] - S. W. BARNETT ET AL, "Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant", JOURNAL OF VIROLOGY, (20100414), vol. 84, no. 12, doi:10.1128/JVI.02533-09, ISSN 0022-538X, pages 5975 - 5985, XP055041222 [Y] 1-61 * abstract * DOI: http://dx.doi.org/10.1128/JVI.02533-09
		[Y] - MOK H ET AL, "Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 81, no. 24, doi:10.1128/JVI.01351-07, ISSN 0022-538X, (20071201), pages 13710 - 13722, (20071010), XP002510798 [Y] 1-61 * abstract * DOI: http://dx.doi.org/10.1128/JVI.01351-07
		[A] - B. R. ANDERSON ET AL, "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", NUCLEIC ACIDS RESEARCH, (20100901), vol. 38, no. 17, doi:10.1093/nar/gkq347, ISSN 0305-1048, pages 5884 - 5892, XP055041208 [A] 1 * abstract * DOI: http://dx.doi.org/10.1093/nar/gkq347
		[A] - Frances Maria Saccoccio, "Thesis: CMV VACCINE DEVELOPMENT BASED ON EPITHELIAL ENTRY MEDIATORS UL128, UL130, AND UL131", (20110603), URL: https://digarchive.library.vcu.edu/bitstream/handle/10156/3452/SACCOCCIO_FRANCES_PhD.pdf?sequence=1, (20140318), XP055108668 [A] 18,38,58 * Impact on future vaccine design; page 160 * * chapter: PEPTIDES TO UL130 AND UL131 NEUTRALIZE CMV INFECTION OF MUCOSAL EPITHELIAL CELLS; page 96 *
		[A] - NÃ SLUND TANJA I ET AL, "Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, (20110124), vol. 8, no. 1, doi:10.1186/1743-422X-8-36, ISSN 1743-422X, page 36, XP021089812 [A] 1 * abstract * DOI: http://dx.doi.org/10.1186/1743-422X-8-36
		[A] - DEFANG G N ET AL, "Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 2, ISSN 0264-410X, (20101216), pages 212 - 220, (20101102), XP027539081 [A] 1 * abstract *
		[A] - BARNEY S. GRAHAM, "Biological challenges and technological opportunities for respiratory syncytial virus vaccine development", IMMUNOLOGICAL REVIEWS, (20110101), vol. 239, no. 1, doi:10.1111/j.1600-065X.2010.00972.x, ISSN 0105-2896, pages 149 - 166, XP055008499 [A] 1-61 * abstract * DOI: http://dx.doi.org/10.1111/j.1600-065X.2010.00972.x
		[A] - ELLIOTT ET AL, "Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques", VACCINE, ELSEVIER LTD, GB, (20070927), vol. 25, no. 41, doi:10.1016/J.VACCINE.2007.07.065, ISSN 0264-410X, pages 7132 - 7144, XP022276667 [A] 1-61 * abstract * DOI: http://dx.doi.org/10.1016/j.vaccine.2007.07.065
		[A] - THOMPSON JOSEPH M ET AL, "Mucosal and systemic adjuvant activity of alphavirus replicon particles", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 10, doi:10.1073/PNAS.0600287103, ISSN 0027-8424, (20060307), pages 3722 - 3727, (20060227), XP002558655 [A] 1-61 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.0600287103
		[A] - A. S. HIDMARK ET AL, "Humoral Responses against Coimmunized Protein Antigen but Not against Alphavirus-Encoded Antigens Require Alpha/Beta Interferon Signaling", JOURNAL OF VIROLOGY, (20060715), vol. 80, no. 14, doi:10.1128/JVI.02579-05, ISSN 0022-538X, pages 7100 - 7110, XP055068342 [A] 1-61 * abstract * DOI: http://dx.doi.org/10.1128/JVI.02579-05
		[AP] - GRADA M. VAN BLEEK ET AL, "RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses", VACCINE, (20111001), vol. 29, no. 43, doi:10.1016/j.vaccine.2011.07.114, ISSN 0264-410X, pages 7285 - 7291, XP055041333 [AP] 1-61 * abstract * DOI: http://dx.doi.org/10.1016/j.vaccine.2011.07.114
		[A] - CARINE L ET AL, "Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 37, doi:10.1016/J.VACCINE.2008.06.100, ISSN 0264-410X, (20080902), pages 4840 - 4848, (20080721), XP023980044 [A] 1-61 * the whole document * DOI: http://dx.doi.org/10.1016/j.vaccine.2008.06.100
		[A] - REAP ET AL, "Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus", VACCINE, ELSEVIER LTD, GB, (20070928), vol. 25, no. 42, doi:10.1016/J.VACCINE.2007.08.016, ISSN 0264-410X, pages 7441 - 7449, XP022277623 [A] 1-61 * abstract * DOI: http://dx.doi.org/10.1016/j.vaccine.2007.08.016
		[AP] - EMILIA GENINI ET AL, "Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections", JOURNAL OF CLINICAL VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 52, no. 2, doi:10.1016/J.JCV.2011.06.018, ISSN 1386-6532, (20111001), pages 113 - 118, (20110804), XP002672532 [AP] 1-61 * abstract * DOI: http://dx.doi.org/10.1016/J.JCV.2011.06.018
	Examination	WO2005007689
		- WEIYAN ZHU ET AL, "Vaccines for Gonorrhea: Can We Rise to the Challenge?", FRONTIERS IN MICROBIOLOGY, (20110101), vol. 2, doi:10.3389/fmicb.2011.00124, XP055352957 DOI: http://dx.doi.org/10.3389/fmicb.2011.00124
		- JIANQING XU ET AL, "Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes", AIDS, (20061128), vol. 20, no. 18, pages 2293 - 2303, XP055352971 DOI: http://dx.doi.org/10.1097/QAD.0b013e328010ad0c
		- LEE J S ET AL, "Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 47-48, doi:10.1016/J.VACCINE.2006.06.004, ISSN 0264-410X, (20061117), pages 6886 - 6892, (20061117), XP028011413 DOI: http://dx.doi.org/10.1016/j.vaccine.2006.06.004
		- S. W. BARNETT ET AL, "Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant", JOURNAL OF VIROLOGY, (20100414), vol. 84, no. 12, doi:10.1128/JVI.02533-09, ISSN 0022-538X, pages 5975 - 5985, XP055041222 DOI: http://dx.doi.org/10.1128/JVI.02533-09
		- MOK H ET AL, "Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 81, no. 24, doi:10.1128/JVI.01351-07, ISSN 0022-538X, (20071201), pages 13710 - 13722, (20071010), XP002510798 DOI: http://dx.doi.org/10.1128/JVI.01351-07
		- PATTERSON L J ET AL, "Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, (20080901), vol. 8, no. 9, doi:10.1517/14712598.8.9.1347, ISSN 1471-2598, pages 1347 - 1363, XP009184363 DOI: http://dx.doi.org/10.1517/14712598.8.9.1347
		- SEAN C SEMPLE ET AL, "Rational design of cationic lipids for siRNA delivery", NATURE BIOTECHNOLOGY (ADVANCE ONLINE PUBLICATION), GALE GROUP INC, vol. 28, no. 2, doi:10.1038/NBT.1602, ISSN 1087-0156, (20100201), pages 172 - 176, (20100117), XP002633693 DOI: http://dx.doi.org/10.1038/NBT.1602
		- GIOVANNA MONTANA ET AL, "Employment of cationic solid-lipid nanoparticles as RNA carriers", vol. 18, no. 2, doi:10.1021/BC0601166, ISSN 1043-1802, (20070301), pages 302 - 308, BIOCONJUGATE CHEMISTRY,, URL: http://pubs.acs.org/doi/abs/10.1021/bc0601166, (20070125), XP002683928 DOI: http://dx.doi.org/10.1021/BC0601166
		- Xingfang Su ET AL, "In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles", Molecular Pharmaceutics, (20110606), vol. 8, no. 3, doi:10.1021/mp100390w, ISSN 1543-8384, pages 774 - 787, XP055127583 DOI: http://dx.doi.org/10.1021/mp100390w
		- TUBULEKAS I ET AL, "Alphavirus expression vectors and their use as recombinant vaccines: a minireview", GENE, ELSEVIER, AMSTERDAM, NL, (19970429), vol. 190, no. 1, doi:10.1016/S0378-1119(96)00679-8, ISSN 0378-1119, pages 191 - 195, XP004064401 DOI: http://dx.doi.org/10.1016/S0378-1119(96)00679-8
		- SAWAI KEISUKE ET AL, "A novel method of cell-specific mRNA transfection", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, AMSTERDAM, NL, (19980501), vol. 64, no. 1, doi:10.1006/MGME.1998.2692, ISSN 1096-7192, pages 44 - 51, XP002245185 DOI: http://dx.doi.org/10.1006/mgme.1998.2692
		- S. W. Barnett ET AL, "Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant", Journal of Virology, (20100414), vol. 84, no. 12, doi:10.1128/JVI.02533-09, ISSN 0022-538X, pages 5975 - 5985, XP055041222 DOI: http://dx.doi.org/10.1128/JVI.02533-09
	by applicant	WO9930733
		WO9728818
		US7604803
		WO2009156852
		WO2009074861
		WO2006061643
		WO2010036948
		US7862829
		WO2011008974
		WO2009079796
		US4373071
		US4458066
		US4500707
		US4668777
		US4973679
		US5047524
		US5132418
		US5153319
		US5262530
		US5700642
		WO2011005799
		WO2005042728
		US5340740
		US5656479
		US5830510
		US6114168
		US6500668
		EP0787180
		EP0329181
		WO03043415
		WO03076601
		US6090619
		US6083741
		US6071890
		WO2009132206
		US2008085870
		US2008057080
		US6054288
		US6048524
		US6048729
		WO0023105
		WO9014837
		US6299884
		US6451325
		US5057540
		WO9633739
		EP0109942
		WO9611711
		WO0007621
		WO03024480
		WO03024481
		EP0689454
		WO0226757
		WO9962923
		WO9840100
		US6207646
		US6239116
		US6429199
		WO0195935
		WO03035836
		US5142047
		US5185444
		WO9517211
		WO9842375
	WO9927960
	US6090406
	US5916588
	EP0626169
	WO9952549
	WO0121207
	WO0121152
	US4689338
	US5389640
	US5268376
	US4929624
	US5266575
	US5352784
	US5494916
	US5482936
	US5346905
	US5395937
	US5238944
	US5525612
	WO2004060308
	WO2004064759
	WO2009111337
	US4186745
	US5397307
	US5547472
	US5674192
	US6129705
	US5580859
	US4945050
	US5036006
	WO2011076807
	WO2011057020
	- GURSEL, M. ET AL., VACCINE, (1999), vol. 17, pages 1376 - 1383
	- KLINMAN, D. M. ET AL., VACCINE, (1999), vol. 17, pages 19 - 25
	- VAJDY, M. ET AL., "Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines", IMMUNOL CELL BIOL, (2004), vol. 82, no. 6, pages 617 - 27
	- SWANSON ET AL., PNAS USA, (2011), vol. 108, no. 23, pages 9619 - 9624
	- KIM ET AL., JMED VIROL, (2007), vol. 79, pages 820 - 828
	- REAP ET AL., VACCINE, (2007), vol. 25, pages 7441 - 7449
	- CHOWDARY ET AL., NATURE STRUCTURAL & MOLECULAR BIOLOGY, (2010), vol. 17, pages 882 - 888
	- LIMBACH ET AL., NUCLEIC ACIDS RESEARCH, (1994), vol. 22, no. 12, pages 2183 - 2196
	- XIONG ET AL., SCIENCE, (1989), vol. 243, pages 1188 - 1191
	- DUBENSKY ET AL., J. VIROL., (1996), vol. 70, pages 508 - 519
	- HARIHARAN ET AL., J. VIROL., (1998), vol. 72, pages 950 - 958
	- POLO ET AL., PNAS, (1999), vol. 96, pages 4598 - 4603
	- LILJESTROM, BIO/TECHNOLOGY, (1991), vol. 9, pages 1356 - 1361
	- BERGLUND ET AL., NAT. BIOTECH., (1998), vol. 16, pages 562 - 565
	- PUSHKO ET AL., VIROLOGY, (1997), vol. 239, pages 389 - 401
	- MASUDA ET AL., NUCLEIC ACIDS SYMPOSIUM SERIES, (2007), vol. 51, pages 3 - 4
	- BEAUCAGE S L ET AL., TETRAHEDRON LETT, (1981), vol. 22, page 1859
	- GAREGG P ET AL., TETRAHEDRON LETT, (1986), vol. 27, pages 4051 - 4
	- FROEHLER B C ET AL., NUCL ACID RES, (1986), vol. 14, pages 5399 - 407
	- GAREGG P ET AL., TETRAHEDRON LETT, (1986), vol. 27, pages 4055 - 8
	- GAFFNEY B L ET AL., TETRAHEDRON LETT, (1988), vol. 29, pages 2619 - 22
	- UHLMANN ET AL., CHEM REV, (1990), vol. 90, pages 544 - 84
	- GOODCHILD J, BIOCONJUGATE CHEM, (1990), vol. 1, page 165
	- Current Protocols in Molecular Biology, GREENE PUBLISH. ASSOC. & WILEY INTERSCIENCE, (1988), vol. 2
	- GLOVER, DNA Cloning, IRL PRESS, (1986), vol. II
	- BITTER ET AL., METHODS IN ENZYMOLOGY, (1987), vol. 153, pages 516 - 544
	- The Molecular Biology of the Yeast Saccharomyces, COLD SPRING HARBOR PRESS, (1982), vol. I, II
	- VACCINE, (2009), vol. 27, pages 4975 - 4982
	- RUIZ-ARGUELLO ET AL., J. GEN. VIROL., (2004), vol. 85, pages 3677 - 3687
	- WU; WU, J. BIOL. CHEM., (1988), vol. 263, page 14621
	- CURIEL ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, page 8850
	- HEYES ET AL., J CONTROLLED RELEASE, (2005), vol. 107, pages 276 - 87
	- Liposomes: Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers: Methods and Protocols, HUMANA PRESS, (2009), vol. 1
	- Liposome Technology, INFORMA HEALTHCARE, (2006), vol. I, II &
	- Functional Polymer Colloids and Microparticles, (2002), vol. 4
	- Functional Polymer Colloids and Microparticles, CITUS BOOKS, (2002), vol. 4
	- O'HAGAN ET AL., J VIROLOGY, (2001), vol. 75, pages 9037 - 9043
	- SINGH ET AL., PHARMACEUTICAL RESEARCH, (2003), vol. 20, pages 247 - 251
	- PODDA, VACCINE, (2001), vol. 19, pages 2673 - 2680
	- FREY ET AL., VACCINE, (2003), vol. 21, pages 4234 - 4237
	- "MF59 - Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines", OTT ET AL., Vaccine Design: The Subunit and Adjuvant Approach, PLENUM PRESS, (1995), pages 277 - 296
	- BARR ET AL., ADV. DRUG DEL. REV., (1998), vol. 32, pages 247 - 271
	- SJOLANDER ET AL., ADV. DRUG DEL. REV., (1998), vol. 32, pages 321 - 338
	- NIIKURA ET AL., VIROLOGY, (2002), vol. 293, pages 273 - 280
	- LENZ ET AL., J. IMMUNOL., (2001), vol. 166, no. 9, pages 5346 - 5355
	- PINTO ET AL., J. INFECT. DIS., (2003), vol. 188, pages 327 - 338
	- GERBER ET AL., J. VIROL., (2001), vol. 75, no. 10, pages 4752 - 4760
	- GLUCK ET AL., VACCINE, (2002), vol. 20, pages 10 - 16
	- MISCHLER; METCALFE, VACCINE, (2002), vol. 20, no. 5, pages B17 - B23
	- JOHNSON ET AL., BIOORG. MED. CHEM. LETT., (1999), vol. 9, pages 2273 - 2278
	- MERALDI ET AL., VACCINE, (2003), vol. 21, pages 2485 - 2491
	- PAJAK ET AL., VACCINE, (2003), vol. 21, pages 836 - 842
	- KANDIMALLA ET AL., NUCL. ACIDS RES., (2003), vol. 31, no. 9, pages 2393 - 2400
	- KRIEG, NAT. MED., (2003), vol. 9, no. 7, pages 831 - 835
	- MCCLUSKIE ET AL., FEMS IMMUNOL. MED. MICROBIOL., (2002), vol. 32, pages 179 - 185
	- KANDIMALLA ET AL., BIOCHEM. SOC. TRANS., (2003), vol. 31, pages 654 - 658
	- BLACKWELL ET AL., J. IMMUNOL., (2003), vol. 170, no. 8, pages 4061 - 4068
	- KRIEG, TRENDS IMMUNOL., (2002), vol. 23, no. 2, pages 64 - 65
	- KANDIMALLA ET AL., BBRC, (2003), vol. 306, pages 948 - 953
	- KANDIMALLA ET AL., BIOCHEM. SOC. TRANS., (2003), vol. 3 L, pages 664 - 658
	- BHAGAT ET AL., BBRC, (2003), vol. 300, pages 853 - 861
	- PITHA ET AL., BIOCHEM. BIOPHYS. ACTA, (1970), vol. 204, no. 1, pages 39 - 48
	- PITHA ET AL., BIOPOLYMERS, (1970), vol. 9, no. 8, pages 965 - 977
	- BEIGNON ET AL., INFECT. IMMUN., (2002), vol. 70, no. 6, pages 3012 - 3019
	- PIZZA ET AL., VACCINE, (2001), vol. 19, pages 2534 - 2541
	- PIZZA ET AL., J. MED. MICROBIOL., (2000), vol. 290, no. 4-5, pages 455 - 461
	- SCHARTON-KERSTEN ET AL., INFECT. IMMUN., (2000), vol. 68, no. 9, pages 5306 - 5313
	- RYAN ET AL., INFECT. IMMUN., (1999), vol. 67, no. 12, pages 6270 - 6280
	- PARTIDOS ET AL., IMMUNOL. LETT., (1999), vol. 67, no. 3, pages 209 - 216
	- PEPPOLONI ET AL., VACCINES, (2003), vol. 2, no. 2, pages 285 - 293
	- PINE ET AL., J. CONTROL RELEASE, (2002), vol. 85, no. 1-3, pages 263 - 270
	- DOMENIGHINI ET AL., MOI. MICROBIOL., (1995), vol. 15, no. 6, pages 1165 - 1167
	- SINGH ET AL., J. CONT. RELEASE, (2001), vol. 70, pages 267 - 276
	- ANDRIANOV ET AL., BIOMATERIALS, (1998), vol. 19, no. 1-3, pages 109 - 115
	- PAYNE ET AL., ADV. DRUG DEL. REV., (1998), vol. 31, no. 3, pages 185 - 196
	- STANLEY, CLIN. EXP. DERMATOL., (2002), vol. 27, no. 7, pages 571 - 577
	- JONES, CURR. OPIN. INVESTIG. DRUGS, (2003), vol. 4, no. 2, pages 214 - 218
	- AKDIS ET AL., EUR. J. IMMUNOLOGY, (2003), vol. 33, pages 2717 - 26
	- HANTKE ET AL., EUR. J. BIOCHEM., (1973), vol. 34, pages 284 - 296
	- BASCHANG ET AL., TETRAHEDRON, (1989), vol. 45, no. 20, pages 6331 - 6360
	- HEYES, J.; PALMER, L.; BREMNER, K.; MACLACHLAN, I., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", JOURNAL OF CONTROLLED RELEASE, (2005), vol. 107, pages 276 - 287
	- OTT ET AL., JOURNAL OF CONTROLLED RELEASE, (2002), vol. 79, pages 1 - 5
	- PERRI ET AL., "An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector", J VIROL, (2003), vol. 77, pages 10394 - 10403
	- PERRI ET AL., J. VIROL., (2003), vol. 77, pages 10394 - 10403

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p